B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244

Benzinga · 2d ago
B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $219 to $244.